Delegates at the Labour Party’s annual gathering in Liverpool have stepped up their call for the government to scrap the £330 million data‑services agreement with US‑based Palantir Technologies. Speaking from the conference floor, party members warned that the contract risks eroding patient confidentiality and could damage public confidence in the National Health Service.
Concerns Over Data Security and Privacy
Many delegates argued that handing over sensitive health information to a foreign tech firm opens the door to potential misuse. They pointed out that Palantir’s platforms have been used in surveillance contexts abroad, raising questions about how NHS data would be protected once transferred to the company’s systems. Several speakers urged ministers to consider alternative UK‑based providers that could offer comparable analytics without compromising sovereignty over personal health records.
Political Pressure Mounts Within the Party
The call to cancel the contract is not coming from a fringe element; it reflects a growing unease across Labour’s parliamentary ranks and grassroots organisations. Shadow ministers have begun to voice similar reservations in private meetings, while local party branches have passed motions urging the leadership to take a firmer stance. The conference debate highlighted a broader party strategy to position Labour as the defender of public services against what it perceives as creeping privatisation.
Government Response and Next Steps
So far, the Department of Health and Social Care has defended the Palantir deal, insisting that the contract includes strict safeguards and that the technology will help reduce waiting times by improving hospital flow management. Officials have said they will review any concerns raised during the conference but have not indicated a willingness to terminate the agreement early. Labour delegates have pledged to keep the issue alive, promising to table questions in Parliament and to work with advocacy groups that specialise in digital rights.
Why it Matters
The outcome of this dispute could set a precedent for how the UK handles future collaborations between the NHS and overseas technology firms. If the government yields to Labour’s pressure and cancels the Palantir contract, it may encourage greater scrutiny of similar deals and potentially accelerate the development of home‑grown health‑data solutions. Conversely, if the agreement proceeds despite the backlash, it could deepen concerns about the transparency of NHS procurement and fuel ongoing debates about the balance between innovation and patient privacy in an increasingly digitised healthcare landscape.
